Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis

Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis

A fundamental process in the development and progression of heart failure is fibrotic remodeling, characterized by excessive deposition of extracellular matrix proteins in response to injury. Currently, therapies that effectively target and reverse cardiac fibrosis are lacking, warranting novel ther...

Full description

Bibliographic Details
Main Authors: Thomas C. L. Bracco Gartner, Sandra Crnko, Laurynas Leiteris, Iris van Adrichem, Linda W. van Laake, Carlijn V. C. Bouten, Marie José Goumans, Willem J. L. Suyker, Joost P. G. Sluijter, Jesper Hjortnaes
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
cardiac fibrosis
tissue-engineering
disease modeling
pirfenidone
targeted proteomics
3D cell culture
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.854314/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.854314/full

Similar Items